[{"orgOrder":0,"company":"HepaRegeniX","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Series B Financing","leadProduct":"Undisclosed","moa":"MAPK4","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"HepaRegeniX","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HepaRegeniX \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"1","companyTruncated":"HepaRegeniX \/ Boehringer Ingelheim GmbH"}]

Find Novel Drugs for Hepatology (Liver, Pancreatic, Gall Bladder) under Development in GERMANY

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The proceeds will be used to advance the first MKK4 inhibitor for treatment of acute and chronic liver diseases to the clinics later in 2020.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          January 21, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Undisclosed

                          Sponsor : Boehringer Ingelheim GmbH

                          Deal Size : $12.2 million

                          Deal Type : Series B Financing

                          blank